Skip to main content

Rylaze FDA Approval History

Last updated by Judith Stewart, BPharm on July 1, 2021.

FDA Approved: Yes (First approved June 30, 2021)
Brand name: Rylaze
Generic name: asparaginase erwinia chrysanthemi (recombinant)-rywn
Dosage form: Injection
Company: Jazz Pharmaceuticals plc
Treatment for: Acute Lymphoblastic Leukemia

Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) is an asparagine specific enzyme indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL).

Development timeline for Rylaze

Nov 18, 2022Approval Jazz Pharmaceuticals Announces U.S. FDA Approval of Monday/Wednesday/Friday Intramuscular Dosing Schedule for Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn)
Jun 30, 2021Approval FDA Approves Rylaze for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.